Limits...
Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H - Int. J. Cancer (2014)

Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier estimates of breast cancer-free survival in relation to COX2 rs5277 genotype and ER status. There was a significant interaction between ER status and COX2 rs5277 genotype on risk of early events (pinteraction = 0.015). As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) Among all patients with invasive tumors (Log Rank; p = 0.99). (Adjusted HR 1.01; 95% CI 0.63–1.61; p = 0.97). (b) Among patients with invasive ER-positive tumors (Log Rank; p = 0.36). Adjusted HR adjusted HR 1.30; 95% CI 0.78–2.18; p = 0.32). (c) Among patients with invasive ER-negative tumors (Log Rank; p = 0.021). Adjusted HR 4.41 (95% CI 1.21–16.02; p = 0.024).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225481&req=5

fig02: Kaplan–Meier estimates of breast cancer-free survival in relation to COX2 rs5277 genotype and ER status. There was a significant interaction between ER status and COX2 rs5277 genotype on risk of early events (pinteraction = 0.015). As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) Among all patients with invasive tumors (Log Rank; p = 0.99). (Adjusted HR 1.01; 95% CI 0.63–1.61; p = 0.97). (b) Among patients with invasive ER-positive tumors (Log Rank; p = 0.36). Adjusted HR adjusted HR 1.30; 95% CI 0.78–2.18; p = 0.32). (c) Among patients with invasive ER-negative tumors (Log Rank; p = 0.021). Adjusted HR 4.41 (95% CI 1.21–16.02; p = 0.024).

Mentions: For all patients, rs5277 was not associated with early events ( Fig. 2a; Log Rank 1 df; p = 0.99). Similar results were observed when patients who had received preoperative treatment were included. In a multivariable model including the 570 patients who had not received preoperative treatment, the G/G genotype did not predict early events (HR 1.01; 95% CI 0.63–1.61; p = 0.97), adjusting for tumor size, axillary nodal involvement, age and histological grade III. Adding the use of endocrine treatment, chemotherapy and radiation treatment or WHR and breast volume (either as dichotomous or continuous variables) to the model did not affect the results.


Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H - Int. J. Cancer (2014)

Kaplan–Meier estimates of breast cancer-free survival in relation to COX2 rs5277 genotype and ER status. There was a significant interaction between ER status and COX2 rs5277 genotype on risk of early events (pinteraction = 0.015). As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) Among all patients with invasive tumors (Log Rank; p = 0.99). (Adjusted HR 1.01; 95% CI 0.63–1.61; p = 0.97). (b) Among patients with invasive ER-positive tumors (Log Rank; p = 0.36). Adjusted HR adjusted HR 1.30; 95% CI 0.78–2.18; p = 0.32). (c) Among patients with invasive ER-negative tumors (Log Rank; p = 0.021). Adjusted HR 4.41 (95% CI 1.21–16.02; p = 0.024).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225481&req=5

fig02: Kaplan–Meier estimates of breast cancer-free survival in relation to COX2 rs5277 genotype and ER status. There was a significant interaction between ER status and COX2 rs5277 genotype on risk of early events (pinteraction = 0.015). As this is an ongoing cohort, there are fewer patients with longer follow-up times. (a) Among all patients with invasive tumors (Log Rank; p = 0.99). (Adjusted HR 1.01; 95% CI 0.63–1.61; p = 0.97). (b) Among patients with invasive ER-positive tumors (Log Rank; p = 0.36). Adjusted HR adjusted HR 1.30; 95% CI 0.78–2.18; p = 0.32). (c) Among patients with invasive ER-negative tumors (Log Rank; p = 0.021). Adjusted HR 4.41 (95% CI 1.21–16.02; p = 0.024).
Mentions: For all patients, rs5277 was not associated with early events ( Fig. 2a; Log Rank 1 df; p = 0.99). Similar results were observed when patients who had received preoperative treatment were included. In a multivariable model including the 570 patients who had not received preoperative treatment, the G/G genotype did not predict early events (HR 1.01; 95% CI 0.63–1.61; p = 0.97), adjusting for tumor size, axillary nodal involvement, age and histological grade III. Adding the use of endocrine treatment, chemotherapy and radiation treatment or WHR and breast volume (either as dichotomous or continuous variables) to the model did not affect the results.

Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Show MeSH
Related in: MedlinePlus